| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00439-006-0260-8 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s00439-006-0260-8 |
| P932 | PMC publication ID | 1797064 |
| P698 | PubMed publication ID | 17048007 |
| P5875 | ResearchGate publication ID | 6747741 |
| P50 | author | Panos Deloukas | Q28037258 |
| Mia Wadelius | Q57693303 | ||
| Claes Wadelius | Q114515819 | ||
| P2093 | author name string | David Bentley | |
| Ralph McGinnis | |||
| Suzannah Bumpstead | |||
| Niclas Eriksson | |||
| Jilur Ghori | |||
| Leslie Y Chen | |||
| P2860 | cites work | The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions | Q24310512 |
| Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients | Q24806783 | ||
| The structure of haplotype blocks in the human genome | Q27860500 | ||
| The vitamin K-dependent carboxylase | Q28142213 | ||
| Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity | Q28193877 | ||
| Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin | Q28211706 | ||
| Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. | Q52550127 | ||
| Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. | Q53257773 | ||
| VKORCI haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation | Q58273734 | ||
| A comparative study of the interaction of warfarin with human alpha 1-acid glycoprotein and human albumin | Q69903147 | ||
| Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe | Q71215004 | ||
| Vitamin K-dependent carboxylation. Evidence that at least two microsomal dehydrogenases reduce vitamin K1 to support carboxylation | Q71585774 | ||
| Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 | Q71996232 | ||
| Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk | Q72235656 | ||
| Molecular analysis of Polish patients with factor VII deficiency | Q72698886 | ||
| Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase | Q73374135 | ||
| Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane | Q73853938 | ||
| Complex association of protein C gene promoter polymorphism with circulating protein C levels and thrombotic risk | Q77862329 | ||
| Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin | Q82627288 | ||
| Mechanism of action of warfarin. Warfarin and metabolism of vitamin K 1 | Q95391738 | ||
| Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | Q28242581 | ||
| Identification of the gene for vitamin K epoxide reductase | Q28242592 | ||
| Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles | Q28244409 | ||
| The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats | Q28576911 | ||
| Linkage disequilibrium in humans: models and data | Q30654298 | ||
| A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other | Q33909759 | ||
| Pharmacogenetics of oral anticoagulants | Q34194039 | ||
| Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. | Q34283903 | ||
| The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. | Q34378782 | ||
| CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis | Q34394876 | ||
| Common VKORC1 and GGCX polymorphisms associated with warfarin dose | Q34417386 | ||
| A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. | Q34418092 | ||
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | Q34423204 | ||
| Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin | Q35204081 | ||
| Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases | Q36044569 | ||
| Pharmacogenetics of warfarin: current status and future challenges | Q36597343 | ||
| Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. | Q40442584 | ||
| Evidence of significant contribution from CYP3A5 to hepatic drug metabolism | Q40512770 | ||
| Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention | Q40844377 | ||
| Transport of vitamin K to bone in humans | Q40994165 | ||
| Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations | Q41293004 | ||
| Human P450 metabolism of warfarin | Q41334623 | ||
| A permutation procedure for the haplotype method for identification of disease-predisposing variants | Q43654167 | ||
| Interindividual variability in sensitivity to warfarin--Nature or nurture? | Q43705893 | ||
| A molecular mechanism for genetic warfarin resistance in the rat. | Q43771296 | ||
| Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. | Q44259188 | ||
| Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor | Q44644004 | ||
| Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity | Q44680862 | ||
| Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions | Q44735365 | ||
| Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX. | Q44952808 | ||
| A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. | Q45052744 | ||
| Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. | Q45182121 | ||
| Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans | Q46174502 | ||
| Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants | Q46463315 | ||
| Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. | Q46496005 | ||
| The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen | Q46537717 | ||
| Warfarin dose related to apolipoprotein E (APOE) genotype | Q46542560 | ||
| Apolipoprotein E (APOE) and warfarin dosing in an Italian population | Q46679463 | ||
| Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population | Q46686666 | ||
| Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing | Q46788661 | ||
| Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population | Q46972802 | ||
| Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes | Q47961549 | ||
| Effect of anticoagulant therapy on the hypercoagulable state in patients carrying the factor V Arg506Gln mutation. | Q50854569 | ||
| Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. | Q51599472 | ||
| Pedigree disequilibrium tests for multilocus haplotypes. | Q52010978 | ||
| A simple correction for multiple comparisons in interval mapping genome scans. | Q52052809 | ||
| P433 | issue | 1 | |
| P921 | main subject | (RS)-warfarin | Q407431 |
| P304 | page(s) | 23-34 | |
| P577 | publication date | 2006-10-18 | |
| P1433 | published in | Human Genetics | Q5937167 |
| P1476 | title | Association of warfarin dose with genes involved in its action and metabolism | |
| P478 | volume | 121 |
| Q34273608 | A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy |
| Q28475004 | A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose |
| Q45939541 | A genome-wide association study of acenocoumarol maintenance dosage. |
| Q36835176 | A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose |
| Q36433323 | A multi-factorial analysis of response to warfarin in a UK prospective cohort |
| Q34050936 | A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients |
| Q34085379 | A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans |
| Q43217456 | ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese |
| Q46466680 | Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort |
| Q39483670 | Adherence and variability in warfarin dose requirements: assessment in a prospective cohort |
| Q46254147 | Aging, Genetic Variations, and Ethnopharmacology: Building Cultural Competence Through Awareness of Drug Responses in Ethnic Minority Elders |
| Q46885444 | Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. |
| Q43055152 | An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction |
| Q46639193 | Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients |
| Q37863679 | Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know |
| Q33644101 | Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. |
| Q38734321 | Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes. |
| Q47141762 | Association of Warfarin Therapy with APOE and VKORC1 Genes Polymorphism in Iranian Population |
| Q41478624 | CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy |
| Q89556414 | CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients |
| Q24641999 | CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing |
| Q57293266 | Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White? |
| Q35447163 | Cardiovascular pharmacogenomics |
| Q36366330 | Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group |
| Q59796437 | Characterization of ADME genes variation in Roma and 20 populations worldwide |
| Q38370270 | Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions |
| Q31042226 | Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation |
| Q37606335 | Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement |
| Q36441517 | Clinical application of high throughput molecular screening techniques for pharmacogenomics |
| Q36190185 | Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial |
| Q29006772 | Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer |
| Q27011524 | Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation |
| Q42953232 | Clinically significant CYP2C inhibition by noscapine but not by glucosamine. |
| Q46950581 | Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans |
| Q90731510 | Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study |
| Q35754760 | Comparison of Nine Statistical Model Based Warfarin Pharmacogenetic Dosing Algorithms Using the Racially Diverse International Warfarin Pharmacogenetic Consortium Cohort Database |
| Q39018202 | Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients |
| Q37173330 | Computational challenges of personal genomics |
| Q33354879 | Considerations in using anticoagulant therapy in special patient populations |
| Q42791847 | Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations |
| Q38671676 | Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? |
| Q84020597 | Current role of pharmacogenomics in cardiovascular medicine |
| Q46730724 | Cytochrome P450-mediated warfarin metabolic ability is not a critical determinant of warfarin sensitivity in avian species: In vitro assays in several birds and in vivo assays in chicken. |
| Q34834319 | Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model |
| Q35085288 | Detection of common single nucleotide polymorphisms synthesizing quantitative trait association of rarer causal variants |
| Q40862073 | Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration |
| Q36511894 | Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients |
| Q47688705 | Development of neuro-fuzzy model to explore gene-nutrient interactions modulating warfarin dose requirement |
| Q36954725 | Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements? |
| Q36882317 | Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans |
| Q44495777 | Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population |
| Q46927387 | Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm |
| Q36651620 | Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans |
| Q34969837 | Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers |
| Q45880221 | Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy |
| Q36118277 | Enzyme Polymorphism in Warfarin Dose Management After Pediatric Cardiac Surgery |
| Q37134366 | Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy. |
| Q33410725 | Estimation of the warfarin dose with clinical and pharmacogenetic data |
| Q37264555 | Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics |
| Q37256499 | Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice |
| Q36921008 | Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing |
| Q53142338 | Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers. |
| Q46885448 | Factors influencing warfarin dose requirements in African-Americans |
| Q39676335 | Frequency of Common CYP2C9 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population |
| Q39159490 | Frequency of Common VKORC1 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population. |
| Q92206503 | Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis |
| Q39513879 | Genetic and clinical determinants influencing warfarin dosing in children with heart disease |
| Q43195085 | Genetic and clinical predictors of warfarin dose requirements in African Americans |
| Q35900767 | Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study |
| Q34571746 | Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients |
| Q43216291 | Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. |
| Q37989811 | Genetic determinants of response to cardiovascular drugs |
| Q43230870 | Genetic determinants of warfarin dosing in the Han-Chinese population |
| Q40637492 | Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy |
| Q43268895 | Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients |
| Q31016306 | Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians |
| Q42722363 | Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism |
| Q92339958 | Genetic risk assessment towards warfarin application: Saudi Arabia study with a potential to predict and prevent side effects |
| Q33792352 | Genetic risk factors for major bleeding in patients treated with warfarin in a community setting |
| Q46787525 | Genetic testing for warfarin dosing? Not yet ready for prime time |
| Q37235860 | Genetic testing for warfarin therapy initiation |
| Q37126654 | Genetic variations and their influence on risk and treatment of venous thrombosis |
| Q35989429 | Genetic-based dosing in orthopedic patients beginning warfarin therapy. |
| Q37998525 | Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments |
| Q34934523 | Genetics of warfarin sensitivity in an emergency department population with thromboembolic. |
| Q42910090 | Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese |
| Q34065133 | Genotype-based dosing algorithms for warfarin therapy: data review and recommendations |
| Q38321269 | Genotype-guided coumarin dosing: where are we now and where do we need to go next? |
| Q39787996 | Haplotype synthesis analysis reveals functional variants underlying known genome-wide associated susceptibility loci |
| Q28740452 | High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans |
| Q35037456 | Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing |
| Q42718669 | Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients |
| Q64067200 | Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease |
| Q39537454 | Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. |
| Q36017389 | Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. |
| Q33990428 | Implementing genotype-guided antithrombotic therapy |
| Q38803472 | Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis |
| Q36535843 | Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients |
| Q37372721 | Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans |
| Q27002899 | Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis |
| Q37376879 | Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans |
| Q42713959 | Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage |
| Q50903331 | Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients. |
| Q39471514 | Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients |
| Q33943678 | Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications |
| Q41824237 | Influence of two common polymorphisms in the EPHX1 gene on warfarin maintenance dosage: a meta-analysis |
| Q36965475 | Integrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report. |
| Q37345384 | Inter and intra ethnic variation of vitamin K epoxide reductase complex and cytochrome P450 4F2 genetic polymorphisms and their prevalence in South Indian population |
| Q35076285 | Interaction between warfarin and Chinese herbal medicines |
| Q35092508 | Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy |
| Q42672191 | Interethnic comparisons of important pharmacology genes using SNP databases: potential application to drug regulatory assessments |
| Q39096673 | Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? a study on a cohort of the Egyptian population. |
| Q37146449 | Kidney function influences warfarin responsiveness and hemorrhagic complications |
| Q39846791 | New genetic variant that might improve warfarin dose prediction in African Americans. |
| Q43110258 | Noscapine may increase the effect of warfarin |
| Q38704025 | Nuclear receptors and drug metabolism for the personalization of cancer therapy |
| Q38078754 | Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms |
| Q85059422 | Oral anticoagulation with coumarins for patients with atrial fibrillation and chronic kidney disease? |
| Q41535282 | P-glycoprotein: a clue to vitamin K antagonist stabilization |
| Q37376199 | Perioperative genomic profiles using structure-specific oligonucleotide probes |
| Q36380430 | Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects? |
| Q38254326 | Personalized genomes and cardiovascular disease |
| Q34337948 | Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans |
| Q55717925 | Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants. |
| Q36851081 | Pharmacogenetic typing for oral anti-coagulant response among factor V Leiden mutation carriers. |
| Q27006860 | Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon |
| Q37657531 | Pharmacogenetics in reproductive and perinatal medicine |
| Q34219746 | Pharmacogenetics of anticoagulants. |
| Q37242614 | Pharmacogenetics of oral anticoagulants: a basis for dose individualization |
| Q57805160 | Pharmacogenetics of warfarin dosing in patients of African and European ancestry |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q35870028 | Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials |
| Q57179825 | Pharmacogenomics Aspect of Warfarin Therapy |
| Q91740942 | Pharmacogenomics In Pharmacy Practice: Current Perspectives |
| Q26997380 | Pharmacogenomics and cardiovascular disease |
| Q40161854 | Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus |
| Q42703883 | Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study |
| Q35720540 | Practical Consideration of Genotype Imputation: Sample Size, Window Size, Reference Choice, and Untyped Rate |
| Q35795269 | Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters |
| Q36044022 | Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes |
| Q37989489 | Prediction of warfarin dose: why, when and how? |
| Q92639142 | Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center |
| Q33990441 | Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. |
| Q36439331 | Prioritizing genetic variants for causality on the basis of preferential linkage disequilibrium |
| Q46816940 | Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes |
| Q37169126 | Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy |
| Q44865332 | Replication study of CYP4F2 association with warfarin response in an Israeli population |
| Q34362277 | Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population |
| Q46178713 | SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement |
| Q33733501 | Screening for 392 polymorphisms in 141 pharmacogenes |
| Q46316268 | Shifting paradigms in the pharmacogenetics of warfarin |
| Q37160370 | Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? |
| Q36228428 | The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review |
| Q90950831 | The effect of genetic and nongenetic factors on warfarin dose variability in Qatari population |
| Q53233863 | The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. |
| Q58563966 | The impact of R353Q genetic polymorphism in coagulation factor VII on the initial anticoagulant effect exerted by warfarin |
| Q53159003 | The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement. |
| Q37071087 | The largest prospective warfarin-treated cohort supports genetic forecasting |
| Q50199930 | The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants. |
| Q47256147 | The rs2108622 polymorphism is related to the early risk of ischemic stroke in non-valvular atrial fibrillation subjects under oral anticoagulation |
| Q28483861 | Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians |
| Q37686157 | Trans-ethnic follow-up of breast cancer GWAS hits using the preferential linkage disequilibrium approach |
| Q88395076 | Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation |
| Q37322151 | Understanding the pharmacogenetic approach to warfarin dosing |
| Q37074097 | Use of genetic and nongenetic factors in warfarin dosing algorithms |
| Q38639052 | Use of medication for cardiovascular disease during pregnancy |
| Q46238853 | VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients |
| Q33511512 | VKORC1 haplotypes in five East-Asian populations and Indians |
| Q51622508 | VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. |
| Q42907084 | VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China |
| Q43097180 | Validity of current recommendation for peri-operative interruption of warfarin in Asians |
| Q43708731 | Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians |
| Q54519534 | Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients. |
| Q26746062 | Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences |
| Q38696567 | Warfarin Pharmacogenomics in Diverse Populations. |
| Q34977531 | Warfarin dosage response related pharmacogenetics in Chinese population |
| Q35678294 | Warfarin dose requirement in Turkish patients: the influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VII |
| Q42531773 | Warfarin genotyping using three different platforms |
| Q91063311 | Warfarin loading dose guided by pharmacogenetics is effective and safe in cardioembolic stroke patients - a randomized, prospective study |
| Q28395337 | Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups |
| Q36375431 | Warfarin pharmacogenetics: challenges and opportunities for clinical translation |
| Q46732643 | Warfarin pharmacogenomics: a big step forward for individualized medicine: enlightened dosing of warfarin |
| Q37454438 | Warfarin sensitivity genotyping: a review of the literature and summary of patient experience |
| Q33793086 | Warfarin therapy: in need of improvement after all these years |
Search more.